Yesterday Australian shares closed 1% higher as most sectors surged. The benchmark S&P/ASX200 index rose 33.9 points, at 3480.2 while the All Ordinaries index was up 0.9%, or 30.60 points, at 3416.8. The local mining and energy sectors could be buoyed by the rising gold and oil prices today despite the negative lead from the US.
Yesterday Australian shares plunged sharply, dragged by financial stocks as investors feared the UK banks might need to raise more funds. The unfavorable corporate earnings results also weighed down the market. The benchmark S&P/ASX200 was down 1.5%, or 52.6 points, to 3464.3, while the broader All Ordinaries index lost 1.4%, or 49.1 points, to 3412.2.
Ventracor Limited (ASX:VCR)(PINK:VTCRY) is responding to an article that appeared in today's "The Australian" newspaper, which in the Company's view makes incorrect and misleading allegations regarding the Company and its product the VentrAssist(R) Left Ventricular Assist Device (LVAD).
Last Friday Australian shares ended higher, capping a winning week after reports that the US government was working on a program to help troubled US home owners. The benchmark S&P/ASX200 rose 44.8 points, or 1.27 per cent, at 3,559.1, while the broader All Ordinaries gained 38.2 points, or 1.1 per cent to 3,496.7. The Obama administration's seeking to lower expectations of a quick fix to the financial crisis and the coming earnings reports may send the market to a negative territory.
Yesterday the Australian shares closed lower. The benchmark S&P/ASX200 index ended 52.4 points, or 1.4%, lower at 3683.3, while the broader All Ordinaries shed 56.4 points, or 1.53%, to 3624.0. The market is pessimistic about the company earnings ahead both in Australia and abroad as investors get prepared for the news that would bring some unpleasant surprises.
Cardiac catheter manufacturer CathRx Limited (ASX:CXD) today announced the first sales of its modular diagnostic catheters to its United Kingdom based distributor.
Ventracor Limited (ASX:VCR)(US:VTCRY) today announced that there have now been more than 250 patient implants of the VentrAssist(R) Left Ventricular Assist Device (LVAD).
